Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Smith

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
The ISME Journal|July 2, 2026
Minimising decompression and warming during deep seawater collection increases abundance and activity of autochthonous bacteria and archaeaAlvaro M Plominsky, Logan M Peoples, Matthew Norenberg, et al.
JCO Precision Oncology|September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)Irene Tsung, David C Smith, Elisabeth I Heath, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
The ISME Journal|July 2, 2026
Minimising decompression and warming during deep seawater collection increases abundance and activity of autochthonous bacteria and archaeaAlvaro M Plominsky, Logan M Peoples, Matthew Norenberg, et al.
JCO Precision Oncology|September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)Irene Tsung, David C Smith, Elisabeth I Heath, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
JAMA Oncology|July 26, 2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With NivolumabSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F McDermott, Charles G Drake, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Pageof 17